Our history

Advanced Oncotherapy started operations in 2012 but our history goes back much further than that and is closely linked to some of the successes of ADAM. Explore our key milestones, the people who contributed to position our Company at the forefront of the proton therapy world, and our most recent advances.


1994

Creation of CareCapital, a company focused on developing, owning and leasing healthcare properties to healthcare operators, primarily in the private sector

2006

IPO of CareCapital on the AIM market

2007

Foundation of ADAM (Application of Detectors and Accelerators to Medicine), as a spin-off from CERN (the European Centre for Nuclear Research). The ADAM team, led by Alberto Colussi and Professor Ugo Amaldi, has designed and built the first unit of a linear accelerator for treating cancer, known as LIGHT (Linac for Image Guided Hadron Therapy)

2008

The Large Hadron Collider (LHC), the world’s largest and most powerful particle accelerator, is turned on. ADAM scientists were involved

2012

CareCapital name changed to Advanced Oncotherapy to reflect the demerger of the property development business and the realignment of the Company's strategy with the aim of capitalising on opportunities in the fields of cancer diagnosis and cancer treatment. This laid the foundations for what Advanced Oncotherapy is today

2013

Step change in Advanced Oncotherapy's activities with the acquisition of ADAM
Eight letters of intent secured for the supply of LIGHT machines

2014

Exclusivity agreement with SUNY Upstate Medical University Hospital, NY. Supply agreements with Global IT leader ICT, ScandiNova, VDL and Toshiba

2015

Sale of two LIGHT systems in China and four additional framework agreements signed; Harley Street lease agreement for the UK's first proton therapy centre using the LIGHT System; Operator agreement with CircleHealth for the Harley Street site; and Progress in the technical developments apace with the original timetable.

2016

Key Board and executive appointments in London and Geneva; technological progress on the LIGHT system, with delivery and successful integration of the proton source and RFQ, plus delivery and high power testing of linac accelerating modules; industrialisation agreement with Thales for full commercial roll-out of the LIGHT system; a £24m financing facility agreed with Metric Capital Partners LLP for the development of Harley Street; a £10m subscription by the Board, senior management and MK Trust and an associated open offer, which raised gross proceeds of £3.4m, for further development of the LIGHT system and to support collaboration with Thales; granting of planning permission for Harley Street.


Who we are

We are leaders in the next generation of proton systems which do not require a cyclotron or synchrotron. We develop cost effective treatments which are clinically superior to those currently available.

Read more

Strategy

Our strategy is to provide wider and cost-effective access to radiation treatment through a ground-breaking proton therapy system with superior clinical benefits for cancer patients.

Read more

Leadership Team

Our team is made up of highly skilled professionals who have a wide range of experience in their field.

Read more

Corporate governance

Advanced Oncotherapy is committed to the highest standards of corporate governance, business integrity and professionalism. The Directors recognise the importance of sound corporate governance.

Read more

Values

We have a strong foundation of core company values which underpin everything we do.

Read more

Directors

Our board brings entrepreneurial, commercial and financial leadership.

Read more

Advisers

Their expertise and experience are unmatched. Combined they have over 100 years in radiation oncology and over 45 years of treating patients with proton therapy from around the world.

Read more